Baird served as a co-manager in this offering
AboutAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) recently completed a 3,600,000 share follow-on offering of its common stock at $48.25 per share. Gross proceeds from the offering totaled approximately $173.7 million. The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development expenditures, sales and marketing expenditures, and business development activities, including the potential acquisition or in-licensing of additional assets. The Company offered all of the 3,600,000 shares of common stock and has granted the underwriters an option to purchase an additional 540,000 shares to cover over-allotments.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme(R) (ferumoxytol) Injection for intravenous use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.
For additional information about this transaction, please contact:
- January 2010
- AMAG Pharmaceuticals, Inc.
- Target Location
- North America